Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics Inc. investor David E. Lazar has disclosed effective control of the company, reporting beneficial ownership of 111,000,000 shares of common stock, or about 98% of the class, through convertible preferred stock.
Under a Securities Purchase Agreement dated December 22, 2025, Lazar agreed to buy 300,000 shares of Series AA Preferred Stock, convertible into 6 million common shares for $1.8 million, and 700,000 shares of Series AAA Preferred Stock, convertible into 105 million common shares for $4.2 million, for total consideration of $6 million. Stockholders approved the necessary share increase and conversion on February 26, 2026.
Following this deal, Lazar became Co-Chief Executive Officer and a director, and is expected to serve as Chairman of the Board. He also obtained the right to recommend up to three additional director nominees at a future stockholder meeting and has participation rights in future Indaptus financing transactions.
Jabbour Jerome D reported acquisition or exercise transactions in this Form 4 filing.
Indaptus Therapeutics director receives stock option grant. Indaptus Therapeutics, Inc. granted director Jerome D. Jabbour options to buy 25,000 shares of common stock under its non-employee director compensation program. These options vest over three years in equal quarterly installments, conditioned on his continued service on the board.
Indaptus Therapeutics reports that stockholders approved a set of proposals that enables a change in control, large potential share issuance and structural changes to its charter and bylaws.
Following a prior preferred stock investment by David E. Lazar, stockholders approved issuing common shares upon conversion of 300,000 Series AA and 700,000 Series AAA Convertible Preferred Stock. After the related charter amendment filing, these preferred shares are convertible at Mr. Lazar’s option into 111.0 million common shares, representing about 96.4% of common stock on a fully diluted basis.
Stockholders also authorized the board to implement up to two reverse stock splits in a 1‑for‑2 to 1‑for‑199 range, approved increasing authorized common shares to 1,000,000,000 and allowed stockholder action by written consent. Two directors, Jerome Jabbour and Matthew McMurdo, were elected, giving Mr. Lazar’s nominees a majority of the nine‑member board.
Indaptus Therapeutics, Inc. filed an initial insider ownership report for board member Jerome D. Jabbour on Form 3. This filing establishes his status as a director subject to insider reporting rules. The report does not list any buy, sell, or other share transactions.
Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock. He holds 25,000 shares of common stock directly, as shown in this initial statement of beneficial ownership.
Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.
The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.
The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.
Indaptus Therapeutics entered into warrant repricing agreements with certain holders of warrants to purchase an aggregate 913,638 shares of common stock that were originally issued in 2024 and 2025 at exercise prices ranging from $8.30 to $47.60. The company reduced the exercise price of these warrants to $1.75 per share, which matches the Nasdaq-defined “Minimum Price.” In return, these holders agreed under a voting agreement to vote all their common shares in favor of all proposals at a special stockholder meeting scheduled for February 26, 2026. The board also unilaterally reduced the exercise price to $1.75 for additional warrants and placement agent warrants to purchase an aggregate 762,787 shares from the same financing rounds, leaving all other warrant terms unchanged.
Indaptus Therapeutics director Avraham Ben-Tzvi reported new equity awards. On January 20, 2026, he received 25,000 shares of restricted common stock as compensation under a consulting agreement, and these shares vested in full immediately upon grant. Following this award, he beneficially owns 25,100 shares of Indaptus common stock, including 100 shares held in a Roth IRA.
Separately, on December 23, 2025, he was granted options to purchase 25,000 shares of Indaptus common stock under the company’s non-employee director compensation program. These stock options vest over three years in equal quarterly installments, so long as he continues to serve on the board through each vesting date.
Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock. The options have an exercise price of $2.69 per share and were granted on January 7, 2026 under the company’s non-employee director compensation program. The award vests over three years in equal quarterly installments starting from the grant date, as long as Natan continues to serve on the board through each vesting date. Following this grant, he beneficially holds 25,000 stock options directly.
Indaptus Therapeutics has called a February 26, 2026 special meeting to ask stockholders to approve a transformative recapitalization built around a recent $6.0 million preferred stock investment by David E. Lazar. The company sold 300,000 Series AA and 700,000 Series AAA Convertible Preferred shares at $6.00 each; after stockholder approval these can convert into 111.0 million common shares. Based on 2,242,324 common shares outstanding as of January 21, 2026, full conversion would give the new investor about 96.4% of the fully diluted common, sharply diluting existing holders and concentrating voting power. Proposals also include electing two Lazar nominees to the board, authorizing a reverse stock split in a 1‑for‑2 to 1‑for‑199 range, increasing authorized common from 200,000,000 up to 1,000,000,000 shares, permitting stockholder action by written consent, and related Nasdaq change of control and issuance approvals.